Breaking News
Get 45% Off 0
Is it finally time to sell Nvidia ahead of earnings?
Read More

Henry Schein Buys EVetPractice, Boosts Technology & VAS Arm

By Zacks Investment ResearchStock MarketsDec 18, 2017 09:42PM ET
www.investing.com/analysis/henry-schein-buys-evetpractice-boosts-technology--vas-arm-200274341
Henry Schein Buys EVetPractice, Boosts Technology & VAS Arm
By Zacks Investment Research   |  Dec 18, 2017 09:42PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
HSIC
-2.34%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NXGN
+0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Henry Schein, Inc. (NASDAQ:HSIC) recently completed the buyout of eVetPractice — a provider of cloud-based practice management solutions to veterinary clinics. Although the financial terms of the deal have been kept under wraps, the company expects the deal to prove accretive to its earnings per share post 2018.

Per the company, the eVetPractice will be a part of Henry Schein’s Veterinary Solutions portfolio which comprises AVImark and ImproMed in North America, as well as Vision, RxWorks and RoboVet globally. Notably, eVetPractice is a rapidly growing cloud solutions provider in the United States, with a customer base of around 900. We believe the latest takeover will widen Henry Schein’s customer base and portfolio.

Developments in Technology & VAS

In September, Henry Schein had announced the receipt of Office of the National Coordinator for Health Information Technology (ONC-Health IT) 2015 Edition Health IT Module Certification from Drummond Group LLC for its practice management and electronic health record software — MicroMD.
The company offers a wide range of practice management software systems covering dental, animal health and medical. It has a customer base of more than 95,000 practices, inclusive of MicroMD for physician practices.

Continuing with the slew of developments, the company had earlier announced a partnership between Medical Systems and Simplifeye. The combined entity aimed at creating a mobile experience by integration of Simplifeye with Henry Schein’s MicroMD. Furthermore, this collaboration aims at allowing physicians to provide more customized patient experiences, simplify their practice workflows and keep concerned team members well connected when away from their workplaces.

Performance of Technology and VAS

We believe this latest development will boost sales in the company’s global Technology and Value-added Services (VAS) business. Interestingly, this segment saw a 4.1% increase in revenues in the last reported quarter. This included 3.7% growth in local currencies and a 0.4% rise related to foreign currency exchange. Acquisitions contributed 0.7% in the quarter under review.

Market Potential

According to a report by MarketsandMarkets, the global veterinary software market is expected to reach a value of $368.7 million by 2019, at a CAGR of 5.6% during 2014 to 2019. Considering the substantial potential of the market, we believe the latest development is a strategic one.

Per the company, the increasing trend toward cost control has the potential to drive the demand for technology solutions. Going by another report from MarketsandMarkets, the global healthcare IT market is projected to reach a value of $280.25 billion at a CAGR of 15.9% in the 2016-2021 period.

We believe an ageing population, unhealthy lifestyle along with rising awareness and expenditure in healthcare will continue to drive growth in the healthcare IT market. This market is dominated by a number of well-established players, the NextGen division of Quality Systems, Inc. (NASDAQ:QSII) being a prominent one.

Share Price Performance

Henry Schein Buys EVetPractice, Boosts Technology & VAS Arm
 

Related Articles

Henry Schein Buys EVetPractice, Boosts Technology & VAS Arm

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email